Edition:
United States

Celgene Corp (CELG.O)

CELG.O on Nasdaq

143.78USD
21 Sep 2017
Change (% chg)

$-0.46 (-0.32%)
Prev Close
$144.24
Open
$143.84
Day's High
$144.59
Day's Low
$143.02
Volume
2,658,336
Avg. Vol
3,774,129
52-wk High
$144.59
52-wk Low
$96.93

Chart for

About

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology... (more)

Overall

Beta: 1.89
Market Cap(Mil.): $112,846.30
Shares Outstanding(Mil.): 782.35
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 78.94 16.33
EPS (TTM): -- -- --
ROI: -- 2.84 14.66
ROE: -- 4.61 13.99

BRIEF-Acceleron Pharma says entered into an agreement with Celgene Corp

* Acceleron Pharma - on September 18, 2017, co and Celgene Corporation entered into an amended and restated collaboration, license and option agreement

Sep 19 2017

BRIEF-Alvogen unit confirms ANDA filing and patent challenge for generic Revlimid

* Alvogen subsidiary confirms ANDA filing and patent challenge for generic Revlimid

Sep 11 2017

BRIEF-Celgene's ESMO data further evaluates drug's potential to treat various cancers

* Data presented at ESMO 2017 further evaluate role of Abraxane® for patients with historically challenging cancers Source text for Eikon: Further company coverage:

Sep 08 2017

FDA widens holds on immunotherapy combination blood cancer trials

U.S. health regulators stopped five blood cancer trials testing AstraZeneca Plc's immunotherapy Imfinzi in combination with Celgene Corp medicines from accepting new patients and halted another study entirely, the companies said on Thursday.

Sep 07 2017

UPDATE 2-FDA widens holds on immunotherapy combination blood cancer trials

Sept 7 U.S. health regulators stopped five blood cancer trials testing AstraZeneca Plc's immunotherapy Imfinzi in combination with Celgene Corp medicines from accepting new patients and halted another study entirely, the companies said on Thursday.

Sep 07 2017

FDA puts Celgene's multiple cancer trials on hold

Sept 7 Celgene Corp said on Thursday the U.S. Food and Drug Administration had placed a partial clinical hold on the company's five trials and a full clinical hold on one trial.

Sep 07 2017

BRIEF-Celgene provides update on the Fusion clinical program

* ‍Patients enrolled in trials on partial clinical hold who are receiving clinical benefit from treatment as determined by investigator,may remain on treatment​

Sep 07 2017

BRIEF-Celgene Corp reports 5.6 percent passive stake in BeiGene as of Aug 31 - SEC filing‍​

* Celgene Corp reports 5.6 percent passive stake in BeiGene as of Aug 31 - SEC filing‍​ Source text : (http://bit.ly/2guND0F) Further company coverage:

Sep 01 2017

BRIEF-Celgene exercised option to extend collaboration with Forma Therapeutics

* Celgene Corporation exercised option to extend strategic collaboration scope and term with Forma Therapeutics Source text for Eikon: Further company coverage:

Aug 29 2017

Grant & Eisenhofer accuses ex-partner of stealing Celgene whistleblower client

Plaintiffs' law firm Grant & Eisenhofer on Thursday sued a former partner who it said engaged in a "treacherous" scheme to steal a client pursuing a whistleblower lawsuit against Celgene Corp that recently settled for $280 million.

Aug 24 2017

Competitors

  Price Chg
Takeda Pharmaceutical Co Ltd (4502.T) ¥6,091 --
Eisai Co., Ltd (4523.T) ¥5,821 --
Johnson & Johnson (JNJ.N) $131.75 -1.47
Novartis AG (NOVN.S) CHF82.95 +0.05
Pfizer Inc. (PFE.N) $35.97 -0.02
Roche Holding Ltd. (ROG.S) CHF249.00 +2.00
Roche Holding Ltd. (RO.S) CHF249.00 +1.40
Merck & Co., Inc. (MRK.N) $65.60 -0.19
Sanofi SA (SASY.PA) €83.87 +1.57
AstraZeneca plc (AZN.L) 4,768.50 +16.50

Earnings vs. Estimates